Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration‑resistant metastatic prostate cancer in adults, only if:

• their disease has progressed on or after 1 docetaxel-containing chemotherapy regimen, and

• the manufacturer provides abiraterone in accordance with the commercial access arrangement as agreed with NHS England.

People currently receiving abiraterone in combination with prednisone or prednisolone whose disease does not meet the criteria in section 1.1 should be able to continue therapy until they and their clinician consider it appropriate to stop.